Oncolysin CD6 (Dana-Farber Cancer Institute)

N/A

Report date: 2022/03/03 17:52:13

Base Information

Drug NameOncolysin CD6 (Dana-Farber Cancer Institute)
Drug Alias NameAnti-CD6-blocked ricinAnti-T12-blocked ricin
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate
Mechanisms of ActionProtein biosynthesis inhibitorsImmunosuppressantsAnti-CD6
TargetsT-cell differentiation antigen CD6
Therapy Area/IndicationsRejection of renal transplantationAutoimmune DiseasesLupus Erythematosus, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunogen IncDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteImmunogen Inc
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationAutoimmune DiseasesLupus Erythematosus, Systemic +[5] 

Other Information

ATC CodeN/A
Related LinksN/A